Table 3 JAK2V617F allele burden (ITT population).

From: Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program

Timepoint

Absolute JAK2V617F allele burden, %

Real baseline (N = 50)

60.1 ± 18.94

Year 1 (N = 42)

48.5 ± 20.01

Year 2 (N = 19)

50.6 ± 21.49

Year 3 (N = 11)

58.9 ± 26.86

Year 4 (N = 10)

47.2 ± 24.71

Year 5 (N = 9)

42.1 ± 14.05

  1. Note that as this is an ongoing study, patients currently in the study have received varying durations of therapy. At the time of these analyses, 31 patients were still in the study. Data are mean ± standard deviation.
  2. JAK Janus kinase.
Back to article page